                         SEQUENCE LISTING

<110>  Grey Wolf Therapeutics Limited
 
<120>  Compounds

<130>  P116141PCT

<140>  PCT/GB2020/051128
<141>  2020-05-07

<150>  GB 1906572.1
<151>  2019-05-09

<150>  GB 1916595.0
<151>  2019-11-14

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  decapeptide substrate


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  dinitrophenyl maleimide (Dnp) residue labeling

<400>  1

Trp Arg Val Tyr Glu Lys Cys Ala Leu Lys 
1               5                   10  


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ovalbumin-specific peptide

<400>  2

Ser Ile Ile Asn Phe Glu Lys Leu 
1               5               


<210>  3
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ER-targeted N-terminally extended precursor peptide derived from 
       ovalbumin

<400>  3

Met Arg Tyr Met Ile Leu Gly Leu Leu Ala Leu Ala Ala Val Cys Ser 
1               5                   10                  15      


Ala Ala Ile Val Met Lys Ser Ile Ile Asn Phe Glu His Leu 
            20                  25                  30  


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  specific recognition complex peptide sequence

<400>  4

Ser Ile Ile Asn Phe Glu His Leu 
1               5               


